Editorial

DOI: 10.4244/EIJ-E-25-00024

The new balloon-expandable Myval transcatheter heart valve: only good news?

Philippe Pibarot1, DVM, PhD; Eric Van Belle2, MD, PhD

As transcatheter aortic valve implantation (TAVI) is increasingly used in younger populations with fewer comorbidities, the long-term durability of transcatheter heart valves (THVs) has become a major issue. Each type of THV features distinct expansion mechanisms, stent frame designs, and leaflet configurations that may influence valve haemodynamic performance, leaflet mechanical stress, and long-term valve durability1. However, direct comparisons of durability beyond 5 years between balloon-expandable (BE) and self-expanding (SE) THVs remain scarce and largely indirect1. Nonetheless, current data suggest that SE THV devices with a supra-annular design may be associated with better durability compared to BE THV devices12.

The Myval/Octacor THV (Meril Life Sciences) is a new balloon-expandable valve that has recently demonstrated non-inferiority to both the SAPIEN 3 BE THV (Edwards Lifesciences) and the Evolut SE THV (Medtronic) at 30-day and 1-year follow-up in the head-to-head LANDMARK and COMPARE-TAVI randomised trials345.

In this issue of EuroIntervention, Jain et al6 assessed the 4-year durability of the Myval/Octacor THV. Although this study shares several limitations with previous studies, including (i) the competing risk of death...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 13
Jul 7, 2025
Volume 21 Number 13
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV15I10A160 Nov 15, 2019
Durability of transcatheter bioprosthetic aortic valves: the story so far
Capodanno D et al
free

10.4244/EIJV11SWA34 Sep 17, 2015
Durability of devices: long-term results and clinical outcomes
Arsalan M and Mack MJ
free

10.4244/EIJV14I15A263 Feb 7, 2019
Valve durability – is this the Achilles’ heel of TAVI?
Jabbour R and Mikhail G
free

10.4244/EIJV12I7A134 Sep 18, 2016
Durability of transcatheter heart valves – much ado about nothing
Prendergast B et al
free

10.4244/EIJV14I4A67 Jul 20, 2018
TAVI durability beyond five years: no alarms, but stay alert
Eltchaninoff H et al
free

10.4244/EIJV14I3A40 Jun 14, 2018
TAVI: a country for old men. Is this durable?
Mylotte D
free

Original Research

10.4244/EIJ-D-24-00662 May 16, 2025
Long-term structural valve deterioration after TAVI: insights from the EORP ESC Valve Durability TAVI Registry
Giannini C et al

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA11 Sep 18, 2016
Patient selection for TAVI in 2016: should we break through the low-risk barrier?
Abdelghani M and Serruys PW
free
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
26.5

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved